225 related articles for article (PubMed ID: 9816051)
1. Potent antileukemic activity of the novel agents norsegoline and dibezine.
Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
[TBL] [Abstract][Full Text] [Related]
2. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of Ph+ progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B.
Waller CF; Ali M; Heinzinger M; Lange W
Anticancer Res; 2000; 20(2A):809-14. PubMed ID: 10810358
[TBL] [Abstract][Full Text] [Related]
5. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Lanza F; Bi S; Castoldi G; Goldman JM
Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
Jazwiec B; Mahon FX; Pigneux A; Pigeonnier V; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1509-14. PubMed ID: 8542939
[TBL] [Abstract][Full Text] [Related]
7. L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.
Martín-Henao GA; Quiroga R; Sureda A; González JR; Moreno V; García J
Haematologica; 2000 Feb; 85(2):139-46. PubMed ID: 10681720
[TBL] [Abstract][Full Text] [Related]
8. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
9. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.
Rizzo MT; Regazzi E; Garau D; Akard L; Dugan M; Boswell HS; Rizzoli V; Carlo-Stella C
Cancer Res; 1999 Oct; 59(19):5047-53. PubMed ID: 10519422
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Schultheis B; Pasternak G; Hehlmann R
Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
[TBL] [Abstract][Full Text] [Related]
13. Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; van der Hem KG; Odding JH; Dräger AM; Ossenkoppele GJ
Br J Cancer; 1999 Mar; 79(9-10):1406-12. PubMed ID: 10188883
[TBL] [Abstract][Full Text] [Related]
14. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
[TBL] [Abstract][Full Text] [Related]
16. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
Straetmans N; Ma DD; Nevell DF; Arthur C
Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
[TBL] [Abstract][Full Text] [Related]
17. Characterization and selection of benign stem cells in chronic myeloid leukemia.
Lemoli RM
Haematologica; 1993; 78(6):393-400. PubMed ID: 8175034
[TBL] [Abstract][Full Text] [Related]
18. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Puccetti E; Güller S; Orleth A; Brüggenolte N; Hoelzer D; Ottmann OG; Ruthardt M
Cancer Res; 2000 Jul; 60(13):3409-13. PubMed ID: 10910048
[TBL] [Abstract][Full Text] [Related]
20. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia.
Jiang YZ; Barrett AJ
Exp Hematol; 1995 Oct; 23(11):1167-72. PubMed ID: 7556526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
